about
Hepatitis G virus infection in primary Sjögren's syndrome: analysis in a series of 100 patientsAdrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patientsDementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patientsCardiac toxicity secondary to long term treatment with chloroquineCardiovascular risk factors and the long-term outcome of lupus nephritis.Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients.Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus.[Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: a report of 3 new cases and a review of the literature]Clinical study and follow-up of 100 patients with the antiphospholipid syndrome.Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome.Cytopenia and past human parvovirus B19 infection in patients with primary Sjögren's syndrome.Splenectomy for refractory Evans' syndrome associated with antiphospholipid antibodies: report of two cases.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases.Systemic lupus erythematosus in men: clinical and immunological characteristics.Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center.Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases.Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies.Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients.The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients.Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients.Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations.[Treatment of systemic lupus erythematosus (II)][Primary antiphospholipid syndrome: clinical and biological study of 36 cases]Anti-beta 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome.Antibodies to thromboplastin in systemic lupus erythematosus: isotype distribution and clinical significance in a series of 92 patients.Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients.Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 80 patients.Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient 'seronegative' antiphospholipid syndrome?Fulminant thrombotic thrombocytopenic purpura in systemic lupus erythematosus.Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients.Giant cell arteritis presenting as a supraclavicular nodulePure sensory neuropathy in patients with primary Sjögren's syndrome: clinical, immunological, and electromyographic findings.Systemic lupus erythematosus in the elderly: clinical and immunological characteristics.Antibodies to endothelial cells in Behçet's disease: cell-binding heterogeneity and association with clinical activity.Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients.Von Willebrand factor in the outcome of temporal arteritisNodular regenerative hyperplasia of the liver and antiphospholipid antibodies: report of two cases and review of the literature.
P50
Q27477922-A6BE5F81-64AE-45CC-A966-408BB1C7C8FAQ28195403-8434133F-A073-4CDC-9828-F91B262DFED0Q28212959-5659773C-0ACE-40D4-B793-E9CCCC093702Q28360029-1046D284-07CA-46DA-833E-F9FD3ED51A91Q31846096-7408A5EC-D114-44A3-9B76-958FE6719DD1Q33239982-8ED6DCE7-8586-40F7-948D-DF7487A080D9Q33329033-AF11CECE-A528-4992-A433-2DA565A3009EQ33330667-55DF2DC1-9E7B-4CAA-8814-FC1E7F54FECCQ33331100-2FA16D58-845F-49EB-8D81-934BDC645227Q33332920-D3D46E4C-79D6-4131-8032-EBF62C01F33DQ33333384-7C55466E-6F5E-4DAE-B260-8028A8998558Q33334858-A06B405E-02B4-463C-B6F8-1EAD00C27C39Q33341941-1D285654-C3D7-480F-9016-C2517413B128Q33346990-171F472D-4B2E-4C2E-BB03-DEDC624EDB99Q33355187-47E31E3B-2DA3-429D-BA63-AD9A63A2EBD4Q33357081-01F0E4B1-6F25-41D8-9571-C3F03E903B26Q33359656-CE3D3CD2-D264-4A06-9B39-209764737327Q33360085-A19C6FD4-CB6C-49F6-95CA-D6FDD1CA1074Q33360771-6380C8BC-B817-4F38-BE23-4D0CAA416D44Q33363684-BB0F804D-2EEE-45F0-9E76-AC94E98A07CDQ33366327-F1B96D13-126E-4C86-9E27-98539386BA42Q33371184-FC8B5314-5198-4210-AF90-09B08F5FF3CEQ33392824-D55F4BA0-159A-4E8C-BEA0-F6C8A69E95A5Q33423945-9624E7BB-9491-4D76-BFA9-110965C8AB62Q33453253-C9F0987B-6CA0-4D19-9B7C-C7EE0A974354Q33492725-6BCAC2D5-BBC2-47A6-9796-B374DCA207FAQ33499072-4D5AB52B-7796-4A2E-935E-C0696EE0C8D7Q33499417-E3622353-26BD-4AB0-8D35-228C4933E09DQ33499605-5D967DD4-B2D7-4435-8927-3DFFF47EC25EQ33500142-41752E94-7B6F-449C-AF38-C4DFC016F193Q33500378-ADAC199A-C927-4437-9EAA-57B607D4F432Q33501931-C7B8C200-C8CC-415B-AF26-377DA0A65AC3Q33502956-1ABADB0B-B9E3-4A8F-872A-C4BC261AB2D4Q33562507-FF63F45D-41AD-4B67-B6DF-AA08692BA80DQ33563036-9252FC7B-50B2-445F-A6A8-9772FFA08744Q33563933-CE351D2D-7EF6-4229-AA1F-C1CB83D2A43AQ33566285-C460EB97-6A08-4FCE-89E6-2901F4FD2A89Q33567403-15C2740F-3F50-4C86-9A75-6C1E810F9CC0Q33579533-76EBC5BF-4730-4D35-B3DB-869CDF2EDB27Q33587613-930D1602-4BB9-4A9D-82B4-349D26EC5C8A
P50
description
forsker
@nb
researcher
@en
name
Miguel Ingelmo
@da
Miguel Ingelmo
@de
Miguel Ingelmo
@en
Miguel Ingelmo
@es
Miguel Ingelmo
@fr
Miguel Ingelmo
@nb
Miguel Ingelmo
@nl
Miguel Ingelmo
@nn
Miguel Ingelmo
@sv
type
label
Miguel Ingelmo
@da
Miguel Ingelmo
@de
Miguel Ingelmo
@en
Miguel Ingelmo
@es
Miguel Ingelmo
@fr
Miguel Ingelmo
@nb
Miguel Ingelmo
@nl
Miguel Ingelmo
@nn
Miguel Ingelmo
@sv
prefLabel
Miguel Ingelmo
@da
Miguel Ingelmo
@de
Miguel Ingelmo
@en
Miguel Ingelmo
@es
Miguel Ingelmo
@fr
Miguel Ingelmo
@nb
Miguel Ingelmo
@nl
Miguel Ingelmo
@nn
Miguel Ingelmo
@sv